NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 2.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,436,858 shares of the medical research company's stock after buying an additional 78,211 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.68% of NeoGenomics worth $56,645,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new stake in shares of NeoGenomics in the fourth quarter valued at $26,000. Versant Capital Management Inc raised its stake in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after purchasing an additional 1,142 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in NeoGenomics by 788.7% in the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after purchasing an additional 3,289 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after purchasing an additional 2,787 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of NeoGenomics by 33.2% during the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after buying an additional 1,103 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director David Brian Perez acquired 10,000 shares of NeoGenomics stock in a transaction that occurred on Monday, May 5th. The shares were purchased at an average cost of $7.63 per share, for a total transaction of $76,300.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at $76,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Jeffrey Scott Sherman bought 20,000 shares of the stock in a transaction on Friday, May 2nd. The shares were acquired at an average price of $7.51 per share, with a total value of $150,200.00. Following the purchase, the chief financial officer now owns 158,494 shares of the company's stock, valued at $1,190,289.94. The trade was a 14.44 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 2.40% of the stock is currently owned by insiders.

NeoGenomics Trading Up 0.5 %

Shares of NASDAQ NEO traded up $0.04 during midday trading on Thursday, hitting $8.04. The stock had a trading volume of 157,668 shares, compared to its average volume of 1,092,705. The company has a fifty day moving average price of $9.27 and a 200 day moving average price of $13.15. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -12.97 and a beta of 1.60. NeoGenomics, Inc. has a 1-year low of $6.08 and a 1-year high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business had revenue of $168.04 million during the quarter, compared to analyst estimates of $171.38 million. During the same period in the previous year, the company earned ($0.02) EPS. NeoGenomics's revenue was up 7.6% on a year-over-year basis. On average, analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

NEO has been the topic of a number of analyst reports. StockNews.com lowered shares of NeoGenomics from a "hold" rating to a "sell" rating in a research report on Monday. Benchmark cut NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Bank of America dropped their target price on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Needham & Company LLC decreased their price target on NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Finally, The Goldman Sachs Group dropped their price objective on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $13.83.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.